Takeda gets ADZYNMA FDA approval for cTTP treatment: A new era in rare disease therapy
Takeda has achieved a monumental milestone in rare disease therapy with the U.S. Food and Drug Administration’s approval of ADZYNMA (ADAMTS13, recombinant-krhn) for the treatment of congenital thrombotic thrombocytopenic purpura (cTTP). This approval marks ADZYNMA as the first and only FDA-approved recombinant ADAMTS13 protein, addressing a critical unmet medical need in people with cTTP by […]